Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Asian Stocks Down on Vaccine Troubles, U.S. Stimulus Fears

Published 10/13/2020, 10:53 PM
Updated 10/13/2020, 11:14 PM
© Reuters.

© Reuters.

By Adam Claringbull

Investing.com – Asia Pacific stocks were mostly down on Wednesday morning after two major U.S. COVID-19 treatment trials were paused over patient safety concerns. Also hampering stocks is the ongoing lack of action on U.S. COVID-19 stimulus plans, with any action looking increasingly likely to be put off until after the U.S. elections.

The Shanghai Composite was up down 0.46% at 11:08 PM ET (3:08 AM GMT) and Shenzhen’s SZSE Composite was down 0.47%. Chinese President Xi Jinping is due to deliver an “important address” in Shenzhen later in the day, marking the 40th anniversary of the establishment of the special economic zone. The speech is expected to lay out greater autonomy for the region.

Japan’s Nikkei 225 inched up 0.07%, reversing some earlier losses. South Korea’s KOSPI fell 0.69%, with the Bank of Korea keeping its key interest rate steady at 0.50% earlier in the day.

Hong Kong’s Hang Seng Index inched up 0.04% and Australia’s S&P/ASX 200 inched down 0.08%.

Asia Pacific markets were subdued in early trading , after Eli Lilly and Co.'s (NYSE:LLY) COVID-19 antibody treatment trial was paused over concerns for patient safety, pulling U.S. markets down by the close of the previous day’s trading. The news follows Johnson & Johnson's (NYSE:JNJ) pause on clinical trials for its COVID-19 vaccine the day before due to a patient illness.

“That just spoke to the fact that a vaccine could take longer to be delivered than what the market’s expectations are calibrated towards,” CommSec market analyst Tom Piotrowski told Reuters.

Adding to investor concerns is the strengthening likelihood of no U.S. COVID-19 stimulus package becoming available until after the Nov. 3 U.S. elections. U.S. House of Representatives Speaker Nancy Pelosi rejected U.S. President Donald Trump’s latest $1.8 trillion COVID-19 as it stands, and even that deal met resistance from the president’s own party, with several Senate Republicans denouncing its cost.

Mark Heppenstall, chief investment officer at Penn Mutual Asset Management had this to say of recent U.S. stimulus events, telling Bloomberg, “It’s been a rollercoaster ride in terms of communication from both sides. There are still going to be significant pockets of stress in the economy.”

However, the increasing odds of a Democrat win at the polls are giving positivity to the markets, as a Democrat stimulus package is anticipated to be far more substantial than the recent deals that have been on offer.

Rising European COVID-19 cases are present further market headwinds, with increased restrictions planned for many countries.

U.K. Prime Minister Boris Johnson has set a deadline of Oct. 15 to finalize the framework of a U.K/E.U trade deal, though there is much skepticism about the likelihood of such a deal being completed in the timeframe.

European Central Bank President Christine Lagarde is to open the virtual annual meetings of the International Monetary Fund and the World Bank Group. The meetings take place over Oct. 12-18.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.